Preventing Premature Ovulation - Shionogi, Nippon Kayaku Receive Approval For Cetrotide
Main Category: FertilityAlso Included In: Women's Health / Gynecology
Article Date: 23 Apr 2006 - 0:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
|
| Healthcare Prof: |  |
5 (1 votes) |
Tokyo, April, 2006 (JCN) - Shionogi and Nippon Kayaku jointly announced on April 20 that they have received approval for Cetrotide, an agent for preventing premature ovulation, from the Ministry of Health, Labor and Welfare.
Cetrotide (cetrorelix acetate), which was developed by German company Zentaris AG, is currently available in 92 countries worldwide.
Nippon Kayaku will import the agent from Zentaris and manufacture it, while Shionogi will market the drug, which is scheduled to be available in September. Through the introduction of Cetrotide, the two companies aim to contribute to fertility treatment in Japan.
By Aki Tsukioka, JCN Staff Writer
Company Profile
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
Visit our fertility section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/42081.php>
APA
http://www.medicalnewstoday.com/releases/42081.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
